A

Amgen

Makes biotech medicines for serious illnesses

Senior Associate Clinical Finish Drug Product Global Study Planner Support

Full-TimeUpdated on 10/24/2026
No salary listed
Junior
Bachelor's, Master's
Hyderabad, Telangana, India
In PersonOn-site in Hyderabad, India.
Operations & LogisticsProduction Planning & Scheduling

About the job

Requirements
  • Bachelor’s degree and at least 5 years of supply chain, logistics, planning, or operations experience, or a Master’s degree and at least 5 years of relevant experience.
  • Demonstrated accurate and efficient handling of process execution in a complex environment.
  • Strong problem-solving and analytical skills for robust decision-making.
  • Good organizational and communication skills, including fluency in spoken and written English and the ability to clearly document and communicate relevant information.
  • Ability to manage assigned tasks and priorities while meeting deadlines.
  • Ability to adapt to evolving priorities in agile clinical studies.
  • Hands-on knowledge of SAP or a similar enterprise resource planning system for material planning and management.
  • Ability to work effectively in cross-functional teams in a regulated or structured environment.
  • Collaborative approach and ability to support shared objectives.
  • Experience or exposure to working with stakeholders in other time zones.
  • Basic understanding of performance metrics, reporting tools, or data tracking processes.
Responsibilities
  • Execute clinical planning processes and related activities to ensure finished drug product is available from study start through study closure.
  • Handle requests for new labeling jobs in the enterprise resource planning system based on system signals.
  • Initiate and follow up stock transfer orders in coordination with the planner’s information about quantities, timing, and destinations.
  • Initiate destruction of finished drug product and follow up on delays or discrepancies.
  • Perform periodic checks and provide input to key performance indicators.
  • Route controlled documents and update text after review workflows in conjunction with subject matter experts.
  • Provide operational oversight across supply planning, order management, and material destruction, and identify problems and inconsistencies.
  • Execute work under clear priorities and support urgent requests as needed.
  • Participate in issue triage, corrective actions, and workload prioritization with global peers.
  • Escalate and resolve planning, procurement, and execution risks in a timely manner.
  • Execute production order conversion, stock transfer order initiation, and clinical planning cycle facilitation to support product supply plans.
  • Execute study closeout activities, including material destruction.
  • Provide subject matter expertise to peers on complex operational processes.
  • Update procedures to keep them current, compliant, and inspection-ready.
  • Provide input to team key performance indicators related to service level, execution timelines, and right-first-time delivery.
  • Conduct root cause analysis and continuous improvement activities to address gaps and improve team outcomes.
  • Adopt new technologies and artificial intelligence to increase team productivity.
  • Represent the team during audits and inspections.
  • Partner with planners, internal and external labeling facilities, company warehouses, logistics service providers, and Quality.
  • Work with local peers to prioritize work and prevent backlogs.
  • Execute work right first time in accordance with applicable good manufacturing practice, good distribution practice, regulatory requirements, and company procedures; report risks, inconsistencies, and errors.
  • Manage workload prioritization and participate in performance management, risk mitigation, and continuous improvement initiatives across teams.
Desired Qualifications
  • Experience with document workflows in Veeva Vault.
  • Experience in regulated manufacturing or the life sciences industry.
  • Exposure to change initiatives, system implementations, or continuous improvement efforts.
  • APICS or Lean/Six Sigma certification.

About the company

Amgen develops and makes biologic medicines, which are drugs built from proteins and antibodies grown in living cells, for serious conditions such as heart disease, cancer, and bone loss. Its anemia drug Epogen, approved in 1989, became one of the biotechnology industry's first blockbuster medicines. Amgen grows these drugs in large tanks called bioreactors, and its products include the cholesterol drug Repatha, the bone-building drug Evenity, and the severe asthma drug Tezspire. It earns money by selling these medicines, mostly through large drug wholesalers that supply hospitals and pharmacies. Amgen was founded in 1980 and is based in Thousand Oaks, California.

Company Size

10,001+

Company Stage

IPO

Headquarters

Thousand Oaks, California

Founded

1980

Get referred to Amgen

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Growth is broad-based: 22 products grew at least 10%, lifting June 2026 quarter revenue 10% to $10.1 billion.
  • Stock grants gained value: Amgen shares rose 27% from January to October 9, 2026, versus 10% for rival Eli Lilly.
  • Many U.S. roles are remote: 145 of Amgen's 615 U.S. job openings in October 2026 were fully remote.

What critics are saying

  • Its 2025 best seller is shrinking: cheaper copies cut bone drug Prolia's sales 32% in the June 2026 quarter.
  • MariTide, Amgen's obesity bet, faces a giant: Lilly's Mounjaro and Zepbound outsold all of Amgen in the June 2026 quarter.
  • Most tech openings are in India: 156 of Amgen's 210 information systems jobs in October 2026 were in Hyderabad.

What makes Amgen unique

  • It copies rivals' blockbusters too: Pavblu, its version of Regeneron's eye drug Eylea, sold $700 million in 2025.
  • Amgen hunts drug targets in a nation's DNA: its Icelandic unit deCODE has genetic data on two-thirds of Iceland's adults.
  • Amgen opened a U.S. cancer-drug class: Blincyto, approved in 2014, was the first to tether immune cells to cancer.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Professional Development Budget
  • Conference Attendance Budget

Company News

Yahoo Finance
Oct 24th, 2026
Amgen vs Johnson & Johnson: cheaper Amgen edges J&J's $94.2B revenue giant on valuation

A Motley Fool comparison of Amgen and Johnson & Johnson (J&J) favours Amgen, mainly on price. Amgen's forward price-to-earnings ratio is 19.4x, against 24.1x for J&J. In 2025, Amgen's revenue rose about 10% to $36.7 billion, with net income of $7.7 billion. J&J's revenue grew 6% to $94.2 billion, with net income of $26.8 billion and free cash flow of $19.7 billion. Amgen carries far more debt: its debt-to-equity ratio is nearly 6.3x, against about 0.6x for J&J. Three wholesalers account for 77% of its gross revenues. Amgen also struck a deal with the US government that exempts it from pharmaceutical tariffs for three years in return for price cuts on two drugs. J&J expects revenue of $101 billion this fiscal year, and Amgen expects about $37.8 billion.

Yahoo Finance
Oct 22nd, 2026
Eli Lilly vs Amgen: $65.2B revenue and 45% growth against a cheaper stock for 2026

Eli Lilly is growing far faster than Amgen, but investors pay a steep premium for it. The article's author favours Lilly for long-term investors in 2026. Lilly's FY 2025 revenue rose 45% to about $65.2 billion, with net income of $20.6 billion and a 32% net margin. Amgen's revenue grew about 10% to $36.7 billion, with net income of $7.7 billion and a 21% margin. Lilly trades at a forward P/E of 38.3x against Amgen's 19.4x. Its debt-to-equity ratio is about 1.6x, compared with nearly 6.3x for Amgen. Lilly's growth rests on its GLP-1 drugs Zepbound and Mounjaro. The article projects 2026 revenue of $88.7 billion, against about $37.8 billion for Amgen.

Yahoo Finance
Oct 21st, 2026
Amgen's focus shifts to six growth drivers and MariTide as rare disease sales hit $1.6B

Amgen now frames its story around six key growth drivers, which grew 26% from a year earlier in fiscal Q2 2026 and made up nearly 70% of product sales. Rare disease, once reported on its own, is one of the six. The rare disease portfolio grew 21% to $1.6 billion, about 16% of quarterly revenue. Total revenue rose 9.5%, and management raised its 2026 revenue guidance to between $38.2 billion and $39.4 billion. Management also highlighted MariTide, an obesity drug in Phase III trials. Amgen wants it to be the first monthly or less frequent obesity therapy and is already scaling up manufacturing. One risk sits in rare disease. On September 1, 2026, Britain's medicines regulator suspended Tavneos for new patients, citing an unreliable main study. The drug made $119 million in fiscal Q1 2026. Amgen's next report is expected around November 3, 2026.

Yahoo Finance
Oct 20th, 2026
Johnson & Johnson and Amgen beat the market in 2026, but can the dividend stocks keep going?

Johnson & Johnson and Amgen, two dividend stocks that have beaten the broader market this year, could suit investors bracing for a possible crash. J&J's latest quarter beat expectations, and it slightly raised its 2026 guidance. But its medtech unit is struggling, as demand for the Impella heart pump has fallen amid safety questions and a US Class 1 recall. Long-term, it has new drugs, a robotic surgery system approved in the US, and a proposed $5.5 billion talc settlement. It is a Dividend King with 64 straight years of payout increases. Amgen's second-quarter revenue rose 10% to $10.1 billion, despite pressure on Tavneos and falling denosumab sales. It has raised payouts 152% over a decade and offers a 2.3% forward yield, against 1.1% for the S&P 500.

Yahoo Finance
Oct 17th, 2026
Amgen raises 2026 revenue forecast to $38.8B as shares gain 15.2%

Amgen raised its fiscal 2026 revenue forecast on August 4 to $38.8 billion at the midpoint, up 2.6% from $37.8 billion. Adjusted earnings per share guidance rose to $22.90 from $22.40. Six key growth drugs grew 26% from a year earlier and made up nearly 70% of product sales in the June quarter. Repatha sales rose 37% to $953 million, offsetting a 33% drop in Prolia and XGEVA sales as biosimilar copies launched. Total revenue rose 10%. The stock has gained 15.2% since the release, against 1.9% for the S&P 500. It closed at $434.03 on October 15, above both its 50-day and 200-day averages. Reaching the midpoint requires $20.1 billion in the second half. Amgen's next report is expected around November 3.